Li, Yuan
Zheng, Ying
Xu, Bing
Cai, Linrui
Feng, Sheng
Liu, Yiming
Zhu, Zhenyi
Yu, Qin
Guo, Hongyan
Clinical trials referenced in this document:
Documents that mention this clinical trial
Safety, Pharmacokinetics, and Pharmacodynamics of SHR7280, a Non-peptide GnRH Antagonist in Premenopausal Women with Endometriosis: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study
https://doi.org/10.1007/s40262-023-01315-6
Funding for this research was provided by:
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Article History
Accepted: 28 September 2023
First Online: 14 October 2023
Declarations
:
: This study was supported by Jiangsu Hengrui Pharmaceuticals Co., Ltd.
: Sheng Feng, Yiming Liu, and Zhenyi Zhu are employees of Jiangsu Hengrui Pharmaceuticals Co., Ltd. Other co-authors declare no competing interests.
: The study was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice Guideline. Study protocol and all amendments were approved by the independent ethics committee of each participating sites.
: All patients provided written informed consent before enrollment.
: Not applicable.
: The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
: HG, QY, and ZZ were responsible for the conception and design of the study. YL, YZ, BX, LC, ZZ, QY, and HG contributed to the data collection. SF and YL was responsible for the statistical analysis. All authors were responsible for data interpretation and manuscript writing, reviewing, and approving for submission.